Equities Analysts Set Expectations for STOK FY2027 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – HC Wainwright boosted their FY2027 earnings per share (EPS) estimates for Stoke Therapeutics in a report issued on Monday, December 15th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings per share of ($2.08) for the year, up from their prior estimate of ($2.41). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2028 earnings at ($0.66) EPS and FY2029 earnings at $1.81 EPS.

Several other research firms have also recently issued reports on STOK. UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a research report on Monday. Canaccord Genuity Group increased their price target on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. BTIG Research reaffirmed a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. Needham & Company LLC upped their price objective on Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a report on Friday, October 10th. Finally, Wedbush increased their price objective on Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $34.78.

Stoke Therapeutics Trading Up 1.9%

Shares of STOK stock opened at $33.61 on Wednesday. The company’s 50-day moving average price is $30.10 and its 200-day moving average price is $21.13. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of 50.16 and a beta of 1.14. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The company had revenue of $10.63 million during the quarter, compared to analysts’ expectations of $6.06 million.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently modified their holdings of STOK. Vanguard Group Inc. raised its holdings in shares of Stoke Therapeutics by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after buying an additional 217,616 shares during the period. Marshall Wace LLP boosted its holdings in Stoke Therapeutics by 7.9% during the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock valued at $26,111,000 after acquiring an additional 168,771 shares during the period. Siren L.L.C. grew its position in Stoke Therapeutics by 12.4% in the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock valued at $14,945,000 after acquiring an additional 247,347 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after purchasing an additional 293,072 shares in the last quarter. Finally, Polar Capital Holdings Plc increased its position in shares of Stoke Therapeutics by 49.8% during the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock worth $31,102,000 after acquiring an additional 439,824 shares during the period.

Insider Activity

In other news, insider Barry Ticho sold 3,662 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $31.34, for a total value of $114,767.08. Following the transaction, the insider directly owned 19,798 shares in the company, valued at approximately $620,469.32. This represents a 15.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 3,978 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $32.28, for a total transaction of $128,409.84. Following the transaction, the general counsel directly owned 11,831 shares of the company’s stock, valued at $381,904.68. The trade was a 25.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 182,166 shares of company stock valued at $5,136,957. Company insiders own 9.50% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.